Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
A large-scale Medicare study suggests that SGLT-2 inhibitors and GLP-1 receptor agonists significantly slow frailty progression in older adults with type 2 diabetes, independent of their cardiovascular benefits, marking a potential shift in
A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential i